ATNX has been the topic of several other research reports. Royal Bank of Canada reaffirmed an outperform rating on shares of Athenex in a research report on Tuesday, March 12th. SunTrust Banks started coverage on shares of Athenex in a research report on Friday, March 29th. They issued a buy rating and a $20.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $20.00.
Shares of ATNX traded up $1.25 during trading hours on Thursday, hitting $14.26. The stock had a trading volume of 790,096 shares, compared to its average volume of 311,879. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.31 and a quick ratio of 2.75. The company has a market cap of $872.40 million, a PE ratio of -9.90 and a beta of 0.03. Athenex has a 1-year low of $9.38 and a 1-year high of $20.90.
In related news, CEO Johnson Yiu Nam Lau purchased 10,000 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were bought at an average price of $11.78 per share, with a total value of $117,800.00. Following the acquisition, the chief executive officer now owns 2,917,422 shares of the company’s stock, valued at approximately $34,367,231.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Perceptive Advisors Llc purchased 100,000 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was bought at an average cost of $12.71 per share, for a total transaction of $1,271,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 157,500 shares of company stock worth $1,967,090 and have sold 132,240 shares worth $1,559,044. 18.80% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in ATNX. Perceptive Advisors LLC grew its stake in Athenex by 77.6% in the 4th quarter. Perceptive Advisors LLC now owns 5,096,022 shares of the company’s stock valued at $32,550,000 after buying an additional 2,226,494 shares in the last quarter. Diag Capital Management LP purchased a new position in Athenex in the 4th quarter valued at approximately $5,445,000. Emory University purchased a new position in Athenex in the 1st quarter valued at approximately $2,312,000. Vanguard Group Inc grew its stake in Athenex by 8.3% in the 3rd quarter. Vanguard Group Inc now owns 1,878,063 shares of the company’s stock valued at $29,185,000 after buying an additional 144,410 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Athenex by 8.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,878,063 shares of the company’s stock valued at $29,185,000 after buying an additional 144,410 shares in the last quarter. Institutional investors and hedge funds own 31.53% of the company’s stock.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Recommended Story: What is a Reverse Stock Split?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.